Adenocarcinoma Endocervical
O Ponto de Partida para o Adenocarcinoma do Cólon
DOI:
https://doi.org/10.26537/citotech.vi9.6904Palavras-chave:
Adenocarcinoma, Endocervical, Citologia cervicovaginal, Vírus do Papiloma Humano, ImunohistoquímicaResumo
O adenocarcinoma endocervical é uma neoplasia cuja incidência tem vindo a aumentar nas últimas décadas. Uma grande percentagem está associada à infeção por HPV de alto risco.
O presente caso de estudo refere-se a uma citologia cervicovaginal em meio líquido, realizada a uma mulher de 60 anos referenciada pela médica de medicina geral e familiar, de forma a investigar a origem de uma anemia ferropénica crónica.
A citologia cervical, inicialmente desenvolvida para o rastreio de lesões pavimentosas, tem demonstrado uma importância crescente na deteção de lesões glandulares, apesar dos desafios inerentes e da sua menor sensibilidade.
O objetivo deste caso é reforçar a importância da citologia cervicovaginal na deteção de neoplasias glandulares do colo do útero de forma atempada. O resultado citológico do presente estudo de caso foi adenocarcinoma endocervical. Sendo que este resultado foi confirmado através da biópsia realizada simultaneamente com a citologia cervicovaginal, cujo diagnóstico histológico foi adenocarcinoma endocervical associado a HPV, tipo Silva B.
O diagnóstico do adenocarcinoma endocervical levou à realização de outros exames complementares de diagnóstico, que permitiram a deteção e identificação de uma neoplasia colorretal concomitante.
Referências
1. Ezzelarab S, El-Husseiny A, Nasreldin M, Ali R, Nabhan A, Abdel-Razek M, et al. Cervical cancer screening by cytology and the burden of epithelial abnormalities in low resource settings: a tertiary-center 42-year study. BMC Womens Health. 2024 Dec 1;24(1).
2. Tatiana Ramírez A, Valls J, Baena A, David Rojas F, Ramírez K, Álvarez R, et al. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study on behalf of the ESTAMPA Study Group. Lancet Reg Health Am. 2023;26:100593.
3. Andersson S, Mints M, Wilander E. Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. Oncol Lett. 2013 Jul;6(1):215–9.
4. Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Vol. 76, Histopathology. Blackwell Publishing Ltd; 2020. p. 112–27.
5. Stolnicu S, Park KJ, Kiyokawa T, Oliva E, McCluggage WG, Soslow RA. Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology. 2021 Mar 1;40:S75–91.
6. Benesch MGK, Ramos-Santillan VO, Rog CJ, Nelson ED, Takabe K. Epidemiology of Adenosquamous Carcinomas. World J Oncol. 2024;15(3):432–53.
7. Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, et al. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015. Int J Cancer. 2020 Feb 1;146(3):810–8.
8. Pulkkinen J, Kares S, Huhtala H, Kholová I. Detection and outcome of endocervical atypia in cytology in primary hpv screening programme. Diagnostics. 2021 Dec 1;11(12).
9. Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathology. 2014 Dec 11;27(12):1559–67.
10. Alemany L, Klaustermeier JE, Lloveras B, Tous S, Guimera N, Clavero O, et al. Articles Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol [Internet]. 2010;11:1048–56. Available from: www.thelancet.com/oncology
11. Bulk S, Berkhof J, Bulkmans NWJ, Zielinski GD, Rozendaal L, Van Kemenade FJ, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. 2006 Jan 16;94(1):171–5.
12. Walboomers JMM, Jacobs M V., Manos MM, Bosch FX, Kummer JA, Shah K V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology. 1999;189(1):12–9.
13. Sung JA, Nikas IP, Kim H, Ryu HS, Lee C. Diagnostic distribution and pitfalls of glandular abnormalities in cervical cytology: a 25-year single-center study. J Pathol Transl Med. 2022 Nov 15;56(6):354–60.
14. Reynolds JP, Salih ZT, Smith AL, Dairi M, Kigen OJ, Nassar A. Cytologic parameters predicting neoplasia in Papanicolaou smears with atypical glandular cells and histologic follow-up: a single-institution experience. J Am Soc Cytopathol. 2018 Jan 1;7(1):7–15.
15. Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix. Int J Cancer. 2016 Sep 1;139(5):1040–5.
16. Ritu Nayar, David C. Wilbur. The Bethesda System for Reporting Cervical Cytology. Third. Cham: Springer International Publishing; 2015.
17. Niu S, Molberg K, Thibodeaux J, Rivera-Colon G, Hinson S, Zheng W, et al. Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. J Am Soc Cytopathol. 2019 May 1;8(3):141–8.
18. Sociedade Portuguesa de Ginecologia, Sociedade Portuguesa de Oncologia. Consensos Nacionais: Cancro Ginecológico 2020. 2022.
19. Singh N, Gilks CB. Annual Review Issue: Gynaecological Pathology: WHO 2020 and Bwyond. Vol. 76. 2020. 112–127 p.
20. De Vivar AD, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, et al. Invasive endocervical adenocarcinoma: Proposal for a new pattern-based classification system with significant clinical implications: A multi-institutional study. International Journal of Gynecological Pathology. 2013 Nov;32(6):592–601.
21. Alvarado-Cabrero I, Parra-Herran C, Stolnicu S, Roma A, Oliva E, Malpica A. The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology. 2021 Mar 1;40(suppl 1):S48–65.
22. Miller RA, Mody DR, Tams KC, Thrall MJ. Glandular Lesions of the Cervix in Clinical Practice A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
23. Bansal B, Gupta P, Gupta N, Rajwanshi A, Suri V. Detecting uterine glandular lesions: Role of cervical cytology. Cytojournal. 2016 Feb 22;13:3.
24. Wilbur DC. Practical issues related to uterine pathology: In situ and invasive cervical glandular lesions and their benign mimics: Emphasis on cytology-histology correlation and interpretive pitfalls. Vol. 29, Modern Pathology. Nature Publishing Group; 2016. p. S1–11.
25. Hussain I, Howard RS, Syed V, Allgäuer M, Gong H, Xing D, et al. A Cell Line-based Immunohistochemical p53 Expression Pattern Control Panel. International Journal of Gynecological Pathology. 2019 Sep 1;38(5):449–58.
26. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: Cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012 Jan 23;7(1).
27. Yu L, Fei L, Liu X, Pi X, Wang L, Chen S. Application of p16/Ki-67 dual-staining cytology in cervical cancers. Vol. 10, Journal of Cancer. Ivyspring International Publisher; 2019. p. 2654–60.
28. Williams NL, Werner TL, Jarboe EA, Gaffney DK. Adenocarcinoma of the Cervix: Should We Treat It Differently? Vol. 17, Current Oncology Reports. Current Medicine Group LLC 1; 2015.
29. Plaxe SC, Saltzstein SL. Estimation of the Duration of the Preclinical Phase of Cervical Adenocarcinoma Suggests That There Is Ample Opportunity for Screening [Internet]. 1999. Available from: http://www.idealibrary.com
30. Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations. Obstetrics and Gynecology. 2020 Apr 1;135(4):869–78.
31. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Vol. 8, Expert Review of Molecular Diagnostics. 2008. p. 599–605.
32. Fernandes H, Devaraju S, Bhat A, Ramachandra P. Role of cervical cytology in the detection of uterine glandular lesions. Medical Journal of Dr DY Patil Vidyapeeth. 2021 Sep 1;14(5):538–42.
33. Maria Correia Katz L, Rolland Souza S, Oliveira Fittipaldi S, De G, Santos M. Concordância entre citologia, colposcopia e histopatologia cervical Agreement between cytology, colposcopy and cervical histopathology.
34. Roma AA, Mistretta TA, De Vivar AD, Park KJ, Alvarado-Cabrero I, Rasty G, et al. New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome. Gynecol Oncol. 2016 Apr 1;141(1):36–42.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2026 Citotech Online - Case Review
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-SemDerivações 4.0.
